<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02895737</url>
  </required_header>
  <id_info>
    <org_study_id>290/16s</org_study_id>
    <nct_id>NCT02895737</nct_id>
  </id_info>
  <brief_title>PROTECT TAVI - Prospective Randomized Outcome Study in TAVI Patients Undergoing Periprocedural Embolic Cerebral Protection With the Claret Sentinel™ Device</brief_title>
  <acronym>PROTECT</acronym>
  <official_title>PROTECT TAVI - Prospective Randomized Outcome Study in TAVI Patients Undergoing Periprocedural Embolic Cerebral Protection With the Claret Sentinel™ Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <brief_summary>
    <textblock>
      This prospective, randomized study was designed to analyse the difference of cerebral
      embolization in patients undergoing transcatheter aortic valve implantation with
      balloon-expandable vs. self-expandable valves by using a cerebral protection system (Claret
      Sentinel™ Device).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total new lesion volume in protected brain regions detected by Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>Day 2-4 post-procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of new cerebral lesions detected by MRI</measure>
    <time_frame>Day 2-4 post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of clinical stroke and/or neurocognitive dysfunction as assessed by neurological and neurocognitive assessments</measure>
    <time_frame>Day 2-4 post-procedure; 6 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Outcome according to the VARC 2 criteria</measure>
    <time_frame>from operation until hospital discharge; 30-days, 6-months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">328</enrollment>
  <condition>Cerebral Embolization During TAVI Using Balloon-expandable vs. Self-expandable Valves</condition>
  <arm_group>
    <arm_group_label>balloon-expandable TAVI without cerebral protection</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient receives a balloon-expandable transcatheter aortic valve replacement without cerebral protection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>balloon-expandable TAVI with cerebral protection</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient receives a balloon-expandable transcatheter aortic valve replacement with cerebral protection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>self-expandable TAVI without cerebral protection</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient receives a self-expandable transcatheter aortic valve replacement without cerebral protection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>self-expandable TAVI with cerebral protection</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient receives a self-expandable transcatheter aortic valve replacement with cerebral protection</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TAVI: Edwards SAPIEN 3, Edwards Lifesciences</intervention_name>
    <arm_group_label>balloon-expandable TAVI without cerebral protection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TAVI: Edwards SAPIEN 3, Edwards Lifesciences; Claret Sentinel™ Cerebral Protection Systems</intervention_name>
    <arm_group_label>balloon-expandable TAVI with cerebral protection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TAVI: CoreValve® Evolut R™, CoreValve Medtronic</intervention_name>
    <arm_group_label>self-expandable TAVI without cerebral protection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TAVI: CoreValve® Evolut R™, CoreValve Medtronic; Claret Sentinel™ Cerebral Protection Systems</intervention_name>
    <arm_group_label>self-expandable TAVI with cerebral protection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with aortic stenosis and indication for transfemoral aortic valve replacement

          -  Freedom of significant stenosis in the area of Truncus brachiocephalicus and left A.
             carotis (CT)

          -  Necessary vessel diameter of 6.5-10 mm in the area of A. carotis communis sinistra and
             9-15 mm in the area of Truncus brachiocephalicus (for delivery of protection system)

          -  Anomalies of aortic arch (&quot;bovine arch&quot; variants):

               1. Direct outflow of left A. carotis communis out of Truncus brachiocephalicus

               2. Conjoint origin of Truncus brachiocephalicus and left A. carotis communis out of
                  aortic arch

          -  The patient has provided written informed consent

        Exclusion Criteria:

          -  Apoplexy/ TIA during the last ½ year

          -  Severe carotid stenosis (&gt;70%)

          -  Symptomatic or asymptomatic carotid stenosis with necessity of TEA or stenting

          -  Relevant psychiatric diseases

          -  Severe/ relevant visual, auditory or cognitive deficits which impede targeted
             anamnesis, neurologic evaluation or consenting.

          -  Severe neurodegenerative or progressive neuromuscular disease and state after severe
             craniocerebral injury with permanent neurologic sequelae and structural cerebral
             diseases

          -  Pronounced kinking/ stenosis or calcification in the area of the right A. radialis/
             brachialis/ subclavia, which impede implantation of the cerebral protection system

          -  Significant stenosis, relevant calcifications, dissections or aneurysmatic alterations
             in the area of Truncus brachiocephalicus and/or A. carotis communis sinistra.

          -  Contraindications for MRI: among others the presence of a non-MRI-compatible pacemaker
             or defibrillator, metal implants in the area to be evaluated, metal fragments in the
             craniocerebral area, allergies, claustrophobia.

          -  Vessel alterations which impede among others the introduction of a 6 French sheath:

               1. Inadequate perfusion in the area of the right upper extremity (pathologic Allen´s
                  test, vessel obstructions, peripheral vascular disease)

               2. Hemodialysis shunt, grafts, or arteriovenous fistulas in the area of right upper
                  extremity

          -  Acute myocardial infarction ≤ 1 month prior to the planned procedure

          -  Every contraindication for the execution of a transfemoral TAVI

          -  Aortic annulus &lt;19 or &gt;27 mm

          -  Combined aortic vitium with predominant insufficiency.

          -  Severly reduced rightventricular function ≤ 20%

          -  Patients who are planned for a hybrid procedure (e.g. conventional operation and TAVI
             or simultaneous coronary intervention at coronary artery disease needing intervention)
             30 days prior to the planned study procedure

          -  Intracardiac thrombus, hematoma, tumor or vegetations confirmed by echocardiography

          -  Endocarditis

          -  Planned concomitant procedure for atrial fibrillation (operative or via catheter
             ablation) during the follow up phase

          -  Need for emergency procedure

          -  Chronic drug-, medication or alcohol abuse

          -  Consuming disease

          -  Life expectancy &lt; 1 year

          -  Dialysis dependency

          -  Patient with legal incapacity, who is not able to understand the essence, meaning and
             consequences of the study

          -  Participation in other interventional clinical trials in the month of study start or
             planned participation during the participation of this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Muenchen, Klinik für Herz- und Gefäßchirurgie</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Bleiziffer, PD Dr.</last_name>
      <phone>00498912180</phone>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2016</study_first_submitted>
  <study_first_submitted_qc>September 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2016</study_first_posted>
  <last_update_submitted>September 6, 2016</last_update_submitted>
  <last_update_submitted_qc>September 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aortic stenosis, transcatheter aortic valve replacement, stroke, ischemic infarction, cerebral embolic protection device</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

